Human gut-microbiome explorations have enriched our understanding ofmicrobial colonization,maturation,and dysbiosis in health-and-disease subsets.The enormousmetabolic potential of gutmicrobes and their role in themai...Human gut-microbiome explorations have enriched our understanding ofmicrobial colonization,maturation,and dysbiosis in health-and-disease subsets.The enormousmetabolic potential of gutmicrobes and their role in themaintenance of human health is emerging,with new avenues to use themas therapeutic agents to overcome human disorders.Microbiome therapeutics are aimed at engineering the gutmicrobiome using additive,subtractive,ormodulatory therapy with an application of native or engineeredmicrobes,antibiotics,bacteriophages,and bacteriocins.This approach could overcome the limitation of conventional therapeutics by providing personalized,harmonized,reliable,and sustainable treatment.Its huge economic potential has been shown in the global therapeuticsmarket.Despite the therapeutic and economical potential,microbiome therapeutics is still in the developing stage and is facing various technical and administrative issues that require research attention.This review aims to address the current knowledge and landscape ofmicrobiome therapeutics,provides an overview of existing health-and-disease applications,and discusses the potential future directions ofmicrobiomemodulations.展开更多
Engineered probiotics can serve as therapeutics based on their ability of produce recombinant immune-stimulating properties.In this study,we built the recombinant Bacillus subtilis WB800 expressing antimicrobial pepti...Engineered probiotics can serve as therapeutics based on their ability of produce recombinant immune-stimulating properties.In this study,we built the recombinant Bacillus subtilis WB800 expressing antimicrobial peptide KR32(WB800-KR32)using genetic engineering methods and investigated its protective effects of nuclear factor-E2-related factor 2(Nrf2)-Kelch-like ECH-associated protein 1(Keap1)pathway activation in intestinal oxidative disturbance induced by enterotoxigenic Escherichia coli(ETEC)K88 in weaned piglets.Twenty-eight weaned piglets were randomly distributed into four treatment groups with seven replicates fed with a basal diet.The feed of the control group(CON)was infused with normal sterilized saline;meanwhile,the ETEC,ETEC+WB800,and ETEC+WB800-KR32 groups were orally administered normal sterilized saline,5×10^(10)CFU(CFU:colony forming units)WB800,and 5×10^(10)CFU WB800-KR32,respectively,on Days 1-14 and all infused with ETEC K881×10^(10)CFU on Days 15-17.The results showed that pretreatment with WB800-KR32 attenuated ETEC-induced intestinal disturbance,improved the mucosal activity of antioxidant enzyme(catalase(CAT),superoxide dismutase(SOD),and glutathione peroxidase(GPx))and decreased the content of malondialdehyde(MDA).More importantly,WB800-KR32 downregulated genes involved in antioxidant defense(GPx and SOD1).Interestingly,WB800-KR32 upregulated the protein expression of Nrf2 and downregulated the protein expression of Keap1 in the ileum.WB800-KR32 markedly changed the richness estimators(Ace and Chao)of gut microbiota and increased the abundance of Eubacterium_rectale_ATCC_33656 in the feces.The results suggested that WB800-KR32 may alleviate ETEC-induced intestinal oxidative injury through the Nrf2-Keap1 pathway,providing a new perspective for WB800-KR32 as potential therapeutics to regulate intestinal oxidative disturbance in ETEC K88 infection.展开更多
基金the MDU RKF fund for financial support vide MDU/DSW/339.
文摘Human gut-microbiome explorations have enriched our understanding ofmicrobial colonization,maturation,and dysbiosis in health-and-disease subsets.The enormousmetabolic potential of gutmicrobes and their role in themaintenance of human health is emerging,with new avenues to use themas therapeutic agents to overcome human disorders.Microbiome therapeutics are aimed at engineering the gutmicrobiome using additive,subtractive,ormodulatory therapy with an application of native or engineeredmicrobes,antibiotics,bacteriophages,and bacteriocins.This approach could overcome the limitation of conventional therapeutics by providing personalized,harmonized,reliable,and sustainable treatment.Its huge economic potential has been shown in the global therapeuticsmarket.Despite the therapeutic and economical potential,microbiome therapeutics is still in the developing stage and is facing various technical and administrative issues that require research attention.This review aims to address the current knowledge and landscape ofmicrobiome therapeutics,provides an overview of existing health-and-disease applications,and discusses the potential future directions ofmicrobiomemodulations.
基金supported by the Zhejiang Provincial Key R&D Program of China(No.2021C02008)the China Agriculture Research System of MOF and MARA(No.CARS-35)+2 种基金the National Natural Science Foundation of China(No.32022079)the Fundamental Research Funds for the Central Universities(No.2022QZJH46)the Taishan Industrial Leading Talents Project.
文摘Engineered probiotics can serve as therapeutics based on their ability of produce recombinant immune-stimulating properties.In this study,we built the recombinant Bacillus subtilis WB800 expressing antimicrobial peptide KR32(WB800-KR32)using genetic engineering methods and investigated its protective effects of nuclear factor-E2-related factor 2(Nrf2)-Kelch-like ECH-associated protein 1(Keap1)pathway activation in intestinal oxidative disturbance induced by enterotoxigenic Escherichia coli(ETEC)K88 in weaned piglets.Twenty-eight weaned piglets were randomly distributed into four treatment groups with seven replicates fed with a basal diet.The feed of the control group(CON)was infused with normal sterilized saline;meanwhile,the ETEC,ETEC+WB800,and ETEC+WB800-KR32 groups were orally administered normal sterilized saline,5×10^(10)CFU(CFU:colony forming units)WB800,and 5×10^(10)CFU WB800-KR32,respectively,on Days 1-14 and all infused with ETEC K881×10^(10)CFU on Days 15-17.The results showed that pretreatment with WB800-KR32 attenuated ETEC-induced intestinal disturbance,improved the mucosal activity of antioxidant enzyme(catalase(CAT),superoxide dismutase(SOD),and glutathione peroxidase(GPx))and decreased the content of malondialdehyde(MDA).More importantly,WB800-KR32 downregulated genes involved in antioxidant defense(GPx and SOD1).Interestingly,WB800-KR32 upregulated the protein expression of Nrf2 and downregulated the protein expression of Keap1 in the ileum.WB800-KR32 markedly changed the richness estimators(Ace and Chao)of gut microbiota and increased the abundance of Eubacterium_rectale_ATCC_33656 in the feces.The results suggested that WB800-KR32 may alleviate ETEC-induced intestinal oxidative injury through the Nrf2-Keap1 pathway,providing a new perspective for WB800-KR32 as potential therapeutics to regulate intestinal oxidative disturbance in ETEC K88 infection.
